Nemaura Medical Granted UK Trademark “Meta Score,” a Digital Biomarker Term for its Metabolic Health Program Loughborough, England, July 21, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a...

Nemaura Medical Launches Metabolic Health Program for Employers and Insurers Launch into commercial markets offers opportunities for faster and wider adoption of Miboko program Loughborough, England, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD)...

Nemaura Medical Launches Beta Version of Its Metabolic Health Program MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial multibillion-dollar market opportunity in healthcare LOUGHBOROUGH, England, Sept. 29, 2021 (GLOBE...